Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector.
Ku Cristy A, Igelman Austin D, Huang Samuel J, Bailey Steven T, Lauer Andreas K, Duncan Jacque L et al.
Voretigene neparvovec-rzyl caused perimacular atrophy in eyes previously treated with a different viral vector, despite visual gains. This highlights potential risks when using different gene therapy vectors in each eye.